Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 9/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
| ▸ | TDO2 | P48775 | 1/20 | 0.31 |
| ▸ | APAF1 | O14727 | 1/20 | 0.31 |
| ▸ | NSD2 | O96028 | 1/20 | 0.31 |
| ▸ | CASP3 | P42574 | 1/20 | 0.31 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.31 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.31 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | IGFBP3 | P17936 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1414925 | 0.81 | SIRT2 (0.34) | SIRT2 | |
| SCHEMBL5750942 | 0.81 | KMT2A (0.33) | SIRT2 | |
| SCHEMBL7831405 | 0.80 | SIRT2 (0.35) | SIRT2 | |
| SCHEMBL5748437 | 0.79 | SIRT2 (0.36) | SIRT2IDO1TDO2APAF1NSD2 | |
| SCHEMBL5750952 | 0.78 | APAF1 (0.34) | APAF1NSD2CASP3SENP8SENP7 | |
| SCHEMBL4024513 | 0.77 | CA12 (0.38) | SIRT2 | |
| SCHEMBL5678341 | 0.76 | KDM4E (0.46) | SIRT2 | |
| SCHEMBL4024355 | 0.74 | SIRT2 (0.41) | SIRT2 | |
| SCHEMBL1414929 | 0.73 | SIRT2 (0.36) | SIRT2IGFBP3 | |
| SCHEMBL1414832 | 0.73 | SIRT2 (0.37) | SIRT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7084149-B2 | Naphthalene derivatives, their production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-08-01 | — | — | US | disclosed |
| EP-1073640-B1 | NAPHTHALENE DERIVATIVES, THEIR PRODUCTION AND USE | TAKEDA PHARMACEUTICAL (JP) | 2005-04-13 | — | — | EP | disclosed |
| US-20030236274-A1 | Naphthalene derivatives, their production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-12-25 | — | — | US | disclosed |
| US-6573289-B1 | Naphthalene derivatives, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-06-03 | — | — | US | disclosed |
| EP-1073640-A1 | NAPHTHALENE DERIVATIVES, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 2001-02-07 | — | — | EP | disclosed |
| WO-1999054309-A1 | NAPHTHALENE DERIVATIVES, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236274-A1 | Naphthalene derivatives, their production and use | CYP17A1, CYP21A2, HSD17B1 | SIRT2 3163/4885PTGS1 141/4885PTGS2 440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.